Antonella Vila

ORCID: 0000-0002-1294-5824
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • PI3K/AKT/mTOR signaling in cancer
  • Angiogenesis and VEGF in Cancer
  • Epigenetics and DNA Methylation
  • Autophagy in Disease and Therapy
  • SARS-CoV-2 and COVID-19 Research
  • Endoplasmic Reticulum Stress and Disease
  • Neurogenetic and Muscular Disorders Research
  • Amyotrophic Lateral Sclerosis Research
  • Vitamin C and Antioxidants Research
  • Genetic Neurodegenerative Diseases
  • Cancer-related gene regulation

University of Buenos Aires
2020-2022

Fundación Ciencias Exactas y Naturales
2020-2022

Instituto de Biotecnología y Biología Molecular
2022

Instituto de Neurología de Buenos Aires
2021

Consejo Nacional de Investigaciones Científicas y Técnicas
2021

Institute of Astronomy and Space Physics
2021

The protein kinase Akt/PKB participates in a great variety of processes, including translation, cell proliferation and survival, as well malignant transformation viral infection. In the last few years, novel Akt posttranslational modifications have been found. However, how these modification patterns affect subcellular localization, target specificity and, general, function is not thoroughly understood. Here, we postulate experimentally demonstrate by acyl-biotin exchange (ABE) assay 3...

10.3389/fcell.2021.626404 article EN cc-by Frontiers in Cell and Developmental Biology 2021-02-15

TDP-43 is a major component of cytoplasmic inclusions observed in neurodegenerative diseases like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). To further understand the role mRNA/protein metabolism proteostasis, we used combined approach with cellular animal models overexpressing form human (TDP-43-ΔNLS), recapitulating ALS/FTD features. We applied HEK293 cells method for labeling de novo translation, surface sensing translation (SUnSET), based on puromycin (PURO)...

10.3389/fncel.2020.594561 article EN cc-by Frontiers in Cellular Neuroscience 2020-12-08
Coming Soon ...